Shares of Theravance (THRX) soar over 18% in the post-trading session after coming off an...

|By:, SA News Editor

Shares of Theravance (THRX) soar over 18% in the post-trading session after coming off an all-day trading halt while awaiting the FDA's decision on its COPD inhaler Breo Ellipta. The stock most recently traded at $33.25, after being halted earlier this morning at $28.01, as the FDA voted solidly in favor of approval.